Canaccord Genuity resumed coverage on Harpoon Therapeutics with a new price target

7/6/22 9:26:38 AM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Canaccord Genuity resumed coverage of Harpoon Therapeutics with a rating of Buy and set a new price target of $16.00

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$HARP

Date	Price Target	Rating	Analyst
1/5/2024	$23.00	Outperform	Oppenheimer
11/20/2023		Outperform	TD Cowen
7/6/2022	$16.00	Buy	Canaccord Genuity
11/11/2021	$25.00 → $19.00	Outperform	SVB Leerink
9/28/2021	$16.00	Neutral → Buy	Citigroup
8/6/2021	$29.00 → $25.00	Outperform	SVB Leerink